Jazz Pharma: A Hot Pick for Smart Buyers

The biopharma firm Jazz Pharmaceuticals is making headlines because its shares have surged nearly 50 percent in the last year. The company focuses on drugs for sleep disorders and cancer, with two main products—Xywav and Xyrem—helping people who suffer from narcolepsy. Those medicines have become the main source of revenue for the company. Recent technical analysis shows that Jazz’s stock is in a strong uptrend. A popular chart‑screening tool highlighted it as one of the best candidates for a “buy” signal. The price has recently touched an all‑time high of about $198, and the trend remains bullish. Support sits just below $187, while a 50‑day moving average is around $176. The relative strength index sits in the middle of its range, suggesting room for further gains.From a fundamentals standpoint, Jazz has an $11. 6 billion market cap and is trading at roughly 44 times earnings on a trailing basis. Analysts project modest revenue growth of about 4 percent this year, but earnings could jump more than 185 percent. Many Wall Street analysts have issued “strong buy” ratings, and price targets range from $188 to $275. Some rating agencies say the stock is fairly valued, while others encourage buying on a dip. The market’s enthusiasm shows up in the numbers of investors following the stock. Over 23, 000 people on one platform and more than a thousand on another expect Jazz to outperform the market. Short interest is under 10 percent of the float, which suggests limited bearish pressure. For investors who are comfortable with a bit of volatility, Jazz could be an attractive addition. The recent dip may present a chance to buy before the price climbs again, but it is wise to set clear risk limits and maintain a diversified portfolio.